VJHemOnc
LightNews LightNews
banner
vjhemonc.bsky.social
VJHemOnc
@vjhemonc.bsky.social
400 followers 50 following 530 posts
The Video Journal of Hematology & Hematological Oncology is dedicated to providing up-to-date information & international expertise🩸🎥 🗞️ #Leusm #Lymsm #MMSM #MDSsm #MPNsm #BMTsm #CTSM #ImmunoOnc #CLLsm #AMLsm #Leukemia #Lymphoma #Myeloma
Posts Replies Media Videos
Pinned
vjhemonc.bsky.social
VJHemOnc @vjhemonc.bsky.social · Nov 18
Welcome!👋🧡

We are a global, open access, expert-led video journal bringing healthcare professionals trustworthy, cutting-edge updates in #HemOnc🔦

🩸Disease areas www.vjhemonc.com/subjects/#all

🎧VJHemOnc Podcast www.vjhemonc.com/podcasts/

📩VJHemOnc Newsletter www.vjhemonc.com/newsletter/
vjhemonc.bsky.social
In an interview from #iwCLL2025, Nicolas Martinez-Calle provides insight into the UNCOVER project, which aims to evaluate inequalities in the diagnosis and survival of patients with CLL in England.

Watch here:

👉 buff.ly/FZdouqO 👈

#CLLsm #Leusm #Leukemia #HemOnc #BloodSky #HemeSky #MedSky
November 11, 2025 at 6:03 PM
vjhemonc.bsky.social
🩸🎥 Approaching TP53-mutated AML: current challenges, ongoing research & novel therapeutic strategies.

Don't miss this insightful roundtable discussion from #iwAL25 with leading experts Eunice Wang, David Sallman, Gabriel Mannis, & Andrew Wei.

Watch now: 👉 buff.ly/VJJUbmz

#AMLsm #Leusm #Leukemia
November 11, 2025 at 10:01 AM
vjhemonc.bsky.social
At #IMS25, we spoke with Lisa Leypoldt, who shared findings from the cytogenetic subgroup analyses of the Phase II GMMG-CONCEPT trial evaluating Isa-KRd in newly diagnosed #myeloma.

Click here to watch:

🎥 buff.ly/Ut0Ne7p

#MMSM #MultipleMyeloma #CTSM #ImmunoOnc #BloodSky #HemeSky #MedSky
November 10, 2025 at 3:29 PM
vjhemonc.bsky.social
Thank you to Ali Taher for speaking with us recently and providing valuable insight into the management of acute complications of #thalassemia that may present to the emergency department.

Watch the interview here:

👉 buff.ly/yL0drrc 👈

#Hematology #BloodSky #HemeSky #MedSky
November 9, 2025 at 3:01 PM
vjhemonc.bsky.social
🎥 Vanthana Bharathi of @mdanderson.bsky.social discusses optimizing preventive care for patients with CLL using evidence-based strategies:

👉 buff.ly/BKMPQGT 👈

#CLLsm #Leusm #Leukemia #HemOnc #iwCLL2025 #BloodSky #HemeSky #MedSky
November 8, 2025 at 2:01 PM
vjhemonc.bsky.social
In an interview from #SOHO2025, @krishpatelmd.bsky.social of @scri.com comments on the potential of NK cell-based therapies for B-cell lymphomas.

Click here to watch:

👉 buff.ly/jMYSlMT 👈

#LYMsm #Lymphoma #HemOnc #BloodSky #HemeSky #MedSky
November 7, 2025 at 6:02 PM
vjhemonc.bsky.social
🎥 Asya Varshavsky-Yanovsky shares insight into a study showing that a high peak in absolute lymphocyte count following cilta-cel infusion in patients with #myeloma predicts for increased risk of delayed neurological toxicities:

👉 buff.ly/MjL0Oku 👈

#CARTcell #MMSM #MultipleMyeloma #ImmunoOnc #IMS25
November 7, 2025 at 10:01 AM
vjhemonc.bsky.social
Recently, Gottfried von Keudell shared the long-term follow-up results from the Phase II ELM-2 study evaluating the efficacy of the bispecific antibody odronextamab in patients with R/R #FollicularLymphoma.

Watch here:

👉 buff.ly/6GUNfkY 👈

#ImmunoOnc #LYMsm #CTSM #TrialUpdate #SOHO2025 #MedSky
November 6, 2025 at 5:42 PM
vjhemonc.bsky.social
What are the key risk factors for the development of bone disease in patients with #thalassemia? 🩸🦴

Julian Waung provided insight into this in a recent interview – watch here:

👉 buff.ly/Oe2kknT 👈

#Hematology #BloodSky #HemeSky #MedSky
November 6, 2025 at 9:29 AM
vjhemonc.bsky.social
At #iwNHL25, Alexey Danilov of @cityofhope.bsky.social and Meghan Thompson of @mskcancercenter.bsky.social sat down to provide an update on BTK-targeting therapies in non-Hodgkin #lymphoma and CLL.🩸

This is a discussion you don't want to miss!

Click here:
🎥 buff.ly/t3TZTiT

#LYMsm #HemOnc
November 5, 2025 at 6:02 PM
vjhemonc.bsky.social
The IMPROVE trial compared the impact of paused versus continuous BTKi therapy during vaccination in patients with CLL.🩸💉

We recently had the pleasure of speaking to Helen Parry to find out more about the study:

🎥 buff.ly/j1K0VV8

#CLLsm #Leusm #Leukemia #CTSM #iwCLL2025 #ImmunoOnc
November 5, 2025 at 1:19 PM
vjhemonc.bsky.social
Check out this fantastic discussion with #lymphoma experts Martin Dreyling & Georg Hess, who discuss key advances in MCL treatment. Topics covered:

🔸 The TRIANGLE trial
🔸 The role of novel agents
🔸 Treatment approaches for frontline and relapsed disease

👉 buff.ly/QbNZjR2

#LymSM #HemOnc
November 4, 2025 at 5:42 PM
vjhemonc.bsky.social
🎥 Mazyar Shadman of @fredhutch.org presents the results of a post hoc analysis & MAIC comparing the outcomes of fit patients treated with zanubrutinib in the SEQUOIA trial to the outcomes of patients treated with AV in AMPLIFY:

👉 buff.ly/paPH5vx 👈

#CLLsm #iwCLL2025 #Leusm #CTSM #BloodSky #HemeSky
November 4, 2025 at 9:29 AM
vjhemonc.bsky.social
It was fantastic to catch up with @jmikhaelmd.bsky.social at #SOHO2025 to gain insight into areas of consensus & controversy in the current & future management of R/R #MultipleMyeloma!🩸

Watch the interview here:

👉 buff.ly/7AoA6tc 👈

#MMsm #Myeloma #ImmunoOnc #HemOnc #BloodSky #HemeSky #MedSky
November 3, 2025 at 3:04 PM
vjhemonc.bsky.social
In an interview from #iwAL25, Tara Lin discusses the possibility of tailoring treatment for secondary AML dependent on mutational profile, highlighting the heterogeneity of this disease.

Watch here:

👉 buff.ly/HbJTfmF 👈

#AMLsm #Leusm #Leukemia #HemOnc #BloodSky
November 2, 2025 at 4:01 PM
vjhemonc.bsky.social
It was great to catch up with the wonderful Anna Schuh at #iwCLL2025 to hear about ongoing efforts to improve the outcomes & care of patients with CLL in resource-limited settings.

Watch the interview here:

🎥 buff.ly/sZGLLe2

#CLLsm #Leusm #Leukemia #HemOnc #BloodSky #HemeSky #MedSky
November 1, 2025 at 2:01 PM
vjhemonc.bsky.social
We recently had the pleasure of interviewing the lovely Payal Desai to hear about several topics in the field of #SickleCellDisease, including the potential of the six-minute walk test as a prognostic tool. 🚶

Learn more here: 👉 buff.ly/iMa7wAa

#Hematology #BloodSky #HemeSky #MedSky
October 31, 2025 at 6:03 PM
vjhemonc.bsky.social
Want to gain insight into the use of bispecific antibodies & other immunotherapies in early lines of treatment for #NonHodgkinLymphoma?🩸

Check out our discussion from #iwNHL25, with leading experts @DocHutchings, @elizabeth_budde, Lorenzo Falchi, & Sameh Gaballa:

🎥 buff.ly/CPiM5kC

#LYMsm #HemOnc
October 31, 2025 at 9:29 AM
vjhemonc.bsky.social
In a recent interview, Jesús San Miguel comments on the updated findings of the Phase III GEM2017FIT trial, which evaluated the efficacy of DaraKRd versus KRd in patients with newly diagnosed #MultipleMyeloma.

Click to watch:

👉 buff.ly/RVZjPoG 👈

#CTSM #TrialUpdate #IMS25 #MMsm #Myeloma #BloodSky
October 30, 2025 at 5:42 PM
vjhemonc.bsky.social
What should the optimal pre-transfusion hemoglobin target be in patients with thalassemia? 🤔🩸

We caught up with Maria Domenica Cappellini recently to find out!

Click here to watch the interview:

🎥 👉 buff.ly/B8HDjTL

#Thalassemia #Hematology #BloodSky #HemeSky #MedSky
October 30, 2025 at 10:01 AM
vjhemonc.bsky.social
#iwAL25 | John DiPersio comments on the challenges of treating T-cell malignancies with bispecific antibody therapy, and shares insights into the development of WU-CART-007, an anti-CD7 allogeneic CAR T-cell product:

🎥 buff.ly/s2zXiCa

#ALLsm #Leusm #ImmunoOnc #HemOnc #BloodSky #HemeSky #MedSky
October 29, 2025 at 5:42 PM
vjhemonc.bsky.social
It was fantastic to catch up with the lovely Meral Beksac at #IMS25 to hear about strategies for improving CAR T-cell responsiveness and overcoming resistance in patients with #MultipleMyeloma.

Watch the interview here:

🎥 buff.ly/Rm44VmO

#MMsm #Myeloma #CARTCell #ImmunoOnc #BloodSky #HemeSky
October 29, 2025 at 9:29 AM
vjhemonc.bsky.social
How should physicians approach the management of patients with CLL who relapse following treatment with a triplet regimen? 💭🩸

Jacob Soumerai discussed this in a recent interview:

🎥 buff.ly/6qCplqB

#CLLsm #Leusm #iwCLL2025 #HemOnc #BloodSky #HemeSky #MedSky
October 28, 2025 at 4:48 PM
vjhemonc.bsky.social
At #SOHO2025, Asfand Yar Cheema of @clevelandclinic.bsky.social stopped by to share insights into the clinical outcomes of patients with #PolycythemiaVera or MDS treated with GLP-1 agonists.

Click here to watch the interview:

👉 buff.ly/KcqIbrj 👈

#MDSsm #MPNsm #HemOnc #BloodSky #HemeSky #MedSky
October 27, 2025 at 5:42 PM
vjhemonc.bsky.social
In an interview from #IMS25, Doris Hansen of @moffittnews.bsky.social outlined the results from a CIBMTR study assessing the safety and efficacy of cilta-cel in R/R #MultipleMyeloma.💉🩸

Watch here:

👉 buff.ly/fMxLmKd 👈

#IMS25 #MMsm #Myeloma #ImmunoOnc #CARTCell @myeloma-society.bsky.social
October 26, 2025 at 3:01 PM